Dyne Therapeutics Valuation
| DYN Stock | USD 12.26 0.14 1.13% |
At this time, the firm appears to be undervalued. Dyne Therapeutics shows a prevailing Real Value of $21.87 per share. The current price of the firm is $12.26. Our model computes the value of Dyne Therapeutics from reviewing the firm fundamentals such as Current Valuation of 804.79 M, shares owned by insiders of 0.68 %, and Shares Owned By Institutions of 99.32 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Dyne Therapeutics' valuation include:
Undervalued
Today
Please note that Dyne Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Dyne Therapeutics is based on 3 months time horizon. Increasing Dyne Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dyne Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dyne Stock. However, Dyne Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.26 | Real 21.87 | Target 50.83 | Hype 12.65 | Naive 15.25 |
The intrinsic value of Dyne Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dyne Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dyne Therapeutics helps investors to forecast how Dyne stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dyne Therapeutics more accurately as focusing exclusively on Dyne Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Dyne Therapeutics' intrinsic value based on its ongoing forecasts of Dyne Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Dyne Therapeutics' closest peers.
Dyne Therapeutics Cash |
|
Dyne Valuation Trend
Knowing Dyne Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Dyne Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Dyne Therapeutics Total Value Analysis
Dyne Therapeutics is currently anticipated to have company total value of 804.79 M with market capitalization of 1.4 B, debt of 23.99 M, and cash on hands of 291.84 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Dyne Therapeutics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
804.79 M | 1.4 B | 23.99 M | 291.84 M |
Dyne Therapeutics Asset Utilization
One of the ways to look at asset utilization of Dyne is to check how much profit was generated for every dollar of assets it reports. Dyne Therapeutics shows a negative utilization of assets of -0.5 percent, losing $0.00502 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Dyne Therapeutics shows how discouraging it operates for each dollar spent on its assets.Dyne Therapeutics Ownership Allocation
The majority of Dyne Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dyne Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dyne Therapeutics. Please pay attention to any change in the institutional holdings of Dyne Therapeutics as this could imply that something significant has changed or is about to change at the company.Dyne Therapeutics Profitability Analysis
Reported Net Loss for the year was (317.42 M) with profit before taxes, overhead, and interest of 0.About Dyne Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Dyne Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Dyne Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Dyne Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Dyne Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Dyne Therapeutics. We calculate exposure to Dyne Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dyne Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.2 M | -2.1 M | |
| Pretax Profit Margin | (1.22) | (1.16) | |
| Operating Profit Margin | (0.94) | (0.89) | |
| Net Profit Margin | 0.17 | 0.18 | |
| Gross Profit Margin | (5.51) | (5.79) |
Dyne Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 94.1 M |
Dyne Therapeutics Current Valuation Indicators
Dyne Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Dyne Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Dyne Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Dyne Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Dyne Therapeutics' worth.When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.